Site 'Tertiary' Navigation:

Lipocine to Present at the 17th Annual Needham Healthcare Conference

SALT LAKE CITY, March 21, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the 17th Annual Needham Healthcare Conference, taking place March 27th – 28th at the Westin New York Grand Central Hotel in New York City.

 (PRNewsfoto/Lipocine Inc.)

 

Lipocine Presentation Details

Date:

Wednesday, March 28th

Time:

12:45pm Eastern Time

Location:

Westin Grand Central Hotel

Webcast:

http://wsw.com/webcast/needham86/lpcn/

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs: TLANDO, LPCN 1111 and LPCN 1107.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, is currently in Phase 2 testing and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.

 

SOURCE Lipocine Inc.

For further information: Morgan Brown, Executive Vice President & Chief Financial Officer, Phone: (801) 994-7383, [email protected]; or Investors: Hans Vitzhum, Phone: (646) 597-6979, [email protected]